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A B S T R A C T
This paper analyses data of 150 female patients undergoing surgical treatment for invasive ductal breast cancer at
the University Hospital for Tumors from January 2006 to January 2007. The control group consisted of 50 healthy
women. The patients were classified into three groups, depending on their tumor differentiation, i.e. grade I, II and III
tumor groups. Each group consisted of 50 patients. Traditional prognostic factors including: age, tumor size and differ-
entiation grade, axillary lymph node status, presence of distant metastases, steroid receptor findings, vascular invasion
of the primary tumor, presence of an extensive intraductal component (EIC) in the primary tumor, HER-2 protein expres-
sion were evaluated. Both the patients’ and controls’ serum levels of proMMP-2 (pro-matrix metalloproteinase-2) were
assessed using the ELISA method. The aim of the study was to assess pathohistological prognostic factors and the level
of serum proMMP-2 in the three patient groups and the controls, compare the relationship between the prognostic factors
and the level of serum proMMP-2 in the patient groups, and upon the results, determine possible features of proMMP-2 as
a prognostic factor in breast cancer patients. The study results showed no difference in proMMP-2 concentrations be-
tween the three patient groups and the controls. No statistically significant difference in the serum proMMP-2 concentra-
tion was found between the patient groups, although the grade III group values were the highest showing a trend toward
statistical significance. Comparison of proMMP-2 and prognostic factors revealed a statistically significant correlation
between proMMP-2 and age in patients with histologic grade I tumors. There was no statistically significant correlation
between circulating proMMP-2 and other pathohistological prognostic factors.
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Introduction
Breast cancer is the most common female malignant
tumor representing 27% of all female cancers, while the
disease is rare among men.
Breast cancer must be regarded as a disease that is
dependent on numerous interactions of both external
and internal (genetic, hormonal and metabolic) factors.
Invasive ductal carcinoma is the most common type of
breast cancer, accounting for 65–80% of all mammary
carcinomas. Its histological picture is characteristically
diverse as regards the growth pattern, cell appearance
and their mitotic activity.
This is an explicitly heterogeneous group of tumors
that covers a full spectrum of favorable to greatly unfa-
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vorable prognostic factors of which the most important
are lymph node status, histologic tumor grade and tumor
size, presence of steroid receptors and HER2/neu status1.
The HER2/neu is a biological prognostic factor, a
proto-oncogene occurring in locus 17q21 and encoding
the 185-KDA transmembrane domain of the epidermal
growth factor receptor. Gene amplification and protein
overexpression of HER2/neu are characteristics of breast
cancer. Several studies have confirmed that HER2/neu
onco-gene overexpression is associated with a poorer
prognosis. The good side of HER2/neu expression is the
possibility of using Herceptin (trastuzumab) therapy, i.e.
monoclonal antibody therapy which specifically targets
HER2/neu protein2,3.
Besides cellular proteins, there are also extracellular
proteins that play a role in the tumor growth and devel-
opment. These include matrix metalloproteinases that
constitute a large family of proteolytic enzymes and are
involved in physiological (the menstrual cycle, bone re-
modeling process, and normal immune response to infec-
tion) and pathological processes of the body. To date,
twentyfive MMPs are described, all of them showing a
zinc-dependent catalytic domain (Zn++) and classified
on the basis of their substrate specificity4.
MMP-2 is a matrix metalloproteinase that plays a key
role in the processes of tumor invasion and metastasis
for their capacity to degrade extracellular matrix pro-
tein5,6. This is especially important in the degradation
process of collagen type IV and gelatin type that forms
basis of the cell basement membrane. MMP-2 includes a
special activation mechanism that requires the presence
of both tissue inhibitor matrix metalloproteinase-2
(TIMP-2) and membrane type-1 matrix metalloproteinase
(MT1-MMP). TIMP-2 binds to the MT1-MMP catalytic
domain of the cell surface. Full activation is achieved
through either intramolecular autocatalytic mechanisms
or plasminogen-plasmin system activation. At low con-
centrations, TIMP-2 functions as a positive regulator of
MT1-MMP, whereas at high concentrations, TIMP-2 as
well as TIMP-3 and TIMP-4 may completely inhibit the
activity of proMMP-24,7,8.
Experimental murine breast carcinoma with brain
metastases shows an increased expression of gelatinases
and MMP-2 activity as compared to normal brain tis-
sue7–11.
There are not enough data available for circulating
matrix metalloproteinases in relation to malignant tu-
mor progression. For this reason, the aim of this study
was to assess the preoperative circulating serum levels of
both proMMP-2 and proMMP-2/TIMP-2 complex in 150
patients with invasive ductal carcinoma of the breast.
The preoperative evaluation included pathohistologic
prognostic factors (tumor size and differentiation grade,
axillary lymph node status, distant metastases, steroid
receptors, vascular invasion, presence of an extensive
intraductal component (EIC) in the primary tumor,
HER-2/neu protein expression) and their relationship
with serum concentrations of proMMP-2 and proMMP-2/
TIM-2. The aim of the study was to compare serum con-
centrations proMMP-2 and proMMP-2/TIM-2 in cancer
patients with healthy controls.
Materials and Methods
The study included 150 patients with primary breast
cancer treated at the Surgical Oncology Department,
University Hospital for Tumors in Zagreb.
According to their tumor differentiation (grade I, II,
III), the patients were classified into three groups of 50
patients each.
All patients underwent either conservative breast
surgery (segmentectomy) with the adjacent lymph node
dissection or breast ablation with axillary dissection. Af-
ter surgery, the material obtained was pathohistologi-
cally processed. This includes fixation of the resection
material using 10% buffered formalin, paraffin embed-
ding of tissue specimens, tissue sectioning in 5ìm slices
and staining with hemalaun-eosin. The slides were ex-
amined by light microscopy to determine tumor grade,
and assess axillary lymph node status, vascular invasion
of tumor tissue and the presence of an extensive intra-
ductal component (EIC). Immunohistochemical staining
using murine monoclonal antibodies to identify steroid
receptors was performed following Microwave Strepta-
vidin ImmunoPeroxidase (MSIP) protocol on the DAKO
Autostainer Universal Staining System. The results of
immunohistochemical staining were assessed by a semi-
-quantitative method, as follows:
• negative reaction (0) – less than 5% of tumor cells were
positive
• weak positive reaction (+) – 5–10% of tumor cells were
positive
• moderate positive reaction (++) – 10–50% of tumor
cells were positive
• strong positive reaction (+++) – more than 50% of tu-
mor cells were positive.
HER-2 protein expression was assessed using Hercep-
Test (DAKO kit, NoK 5204). The test uses standard re-
agents to be placed on a third section of each tumor, and
the scores are defined according to the manufacturer’s
recommendations as follows:
• negative reaction (–): 0–30% of tumor cells with nega-
tive reaction or weak membrane staining
• weak positive reaction (+): >30% positive tumor cells
with partial membrane standing
• moderate positive reaction (++):>30% positive tumor
cells with moderate strong membrane staining
• strong positive reaction (+++): >30% positive tumor
cells with complete strong membrane staining.
Patients in whom immunohistochemical analysis of
HER-2 receptor showed moderate strong positivity (2+)
underwent retesting by use of a hybridization method.
These are molecular methods based on mutual hybrid-
ization of single-stranded complementary nucleic acid se-
quences. The hybridization phase includes two different
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components: a labeled nucleic acid sequence (probe) and
homologous nucleic acid sequence (DNA, RNA) from
fixed cytogenetic material to be used for diagnostic pur-
poses. The probes are labeled with fluorochrome or mac-
romolecules that are strong immune genes (digoxigenin,
biotin). Depending on probe labeling, two hybridization
techniques are distinguished, i.e. FISH – fluorescence in
situ hybridization and CISH – chromogenic in situ hy-
bridization.
Blood samples for MMP-2 test were collected from pa-
tients at primary diagnosis. Serum for MMP-2 test was
separated from venous blood that was collected in a
test-tube, left to clot at room temperature for 30 min and
further centrifuged at 3000 rpm for 10 min. The sepa-
rated serum was kept frozen at –20 °C until needed for
use. The control group consisted of 50 healthy women.
Enzyme-linked immunosorbent test (ELISA) was us-
ed to detect free circulating pro-MMP-2 and proMMP-2-
-TIMP-2 complex levels. A commercial assay kit – Human
Biotrak ELISA system by Amersham Biosciences, Buck-
inghamshire, UK – was used to detect MMP-2. The assay
for total proMMP-2 (RPN2617) identifies the free form of
circulating proMMP-2 and proMMP-2-TIMP-2 complex.
The ProMMP-2-TIMP-2 complex level was assessed in
microtiter plates coated with the monoclonal anti-TIMP-
-2 antibody (clone T2-101, SBA Sciences, Oulu, Finland).
Diluted serum sample and the polyclonal anti-MMP-2
antibody (clone DB-202, SBA Sciences, Oulu, Finland)
were also added. The present MMP-2 was all bound to
the microtiter plate walls, while other serum compo-
nents were removed by washing and aspiration. MMP-2
was detected with the anti-MMP-2 antibody coated with
peroxidase enzyme that serves as enzyme conjugate
(Chemocon International, Temecula, Calif), and the reac-
tion was demonstrated by adding o-phenylendiamine
dihydrochloride enzyme substrate (Sigma, Steinheim,
Germany). Readings were taken on the 450 nm wave-
-length spectrophotometer (Photometer Spectra 2, Tecan-
-Ortho). The sensitivity of the assay for proMMP-2 is
0.37 ng/mL.
All the results were processed using descriptive statis-
tical methods. The ANOVA (one-way analysis of variance)
was used to test the differences between quantitative vari-
ables. To assess the correlation between proMMP-2 and
other prognostic factors for breast cancer linear correla-
tion analysis was employed.
Results
The study included 150 patients. The mean age of all
patients was 59.5 years. According to their tumor differ-
entiation grade, the patients were assigned to one of
three groups of 50 patients each.
The age range in the grade I, grade II and grade III
group was 37–81 years (mean age 59), 45–82 years (mean
age 55.5 years) and 36–83 years (mean 59.5 years) re-
spectively.
Analysis of axillary involvement by lymph node meta-
stases showed 89 lymph node-negative patients (59.3%),
and 61 patients (40.6%) had lymph node metastases.
Analysis of estrogen (ER) and progesterone (PR) re-
ceptors revealed the following: 92 patients (61.3%) with
ER+PR+, 37 patients (24.66%) with ER-PR-, 19 patients
(12.6%) with ER+PR- and 2 patients with ER-PR+. A
comparison of hormone receptors by tumor grade show-
ed a statistically significant difference between grade I
and grade III, and between grade I and grade III tumors.
Among the 150 study patients with invasive ductal
breast cancer, 48 (32%) patients tested positive for the
HER-2 protein, while in 102 (68%) patients the result
was negative.
The presence of vascular invasion was observed in 24
(16%) patients, and its absence was shown in 126 (84%)
patients.
An extensive intraductal component was found in 46
(30.6%) patients, and not documented in 104 (69%) pa-
tients.
A comparison of tumor diameter by tumor grades
showed a statistical significance between grades I and II,
grades I and III, and grades II and III. The largest mean
tumor diameter was in the grade III group, and the
smallest mean tumor diameter was observed in the grade
I group.
Vascular invasion as a negative prognostic factor was
shown to be most pronounced in the grade III. The
HER-2 protein as an important predictor and prognosti-
cator was shown to be comparable in the grade II and III
groups, and the least expressed in the grade I group.
ProMMP-2
A comparison of the serum proMMP-2 level in healthy
controls and patients classified into three histologic tu-
mor grade groups is shown in Table 1. No statistically
significant difference in the proMMP-2 level was found
between of the controls and patient groups (p=0.337).
The highest levels and the highest overall mean of pro-
MMP-2 were reported for the grade III group (Table 1).
To substantiate the statistical significance in a larger pa-
tient sample a further investigation is required
The correlation between the healthy control proMMP-2
level and age was not statistically significant (p=0.175).
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TABLE 1
COMPARISON OF PROMMP-2 LEVELS BETWEEN CONTROLS










N 50 50 50 50
X 1292.54 1224.67 1268.10 1321.82
SD 239.55 293.81 333.44 274.42
sem 33.88 41.55 47.16 38.81
Maximum 1728 1875 1815 2125
Minimum 783 380 255 497
The serum proMMP-2 level in old age had a tendency
towards lower values. The correlation between the pro-
MMP-2 level and age of all breast cancer patients showed
a tendency towards an increase of proMMP-2 concentra-
tions in old age; the finding was statistically significant
(p=0.0021) and actually contrary in relation to this in
healthy controls (Figures 1 and 2).
A comparison of the proMMP-2 level with the number
of positive lymph nodes did not reveal any statistically
significant correlation (p=0.176) between the two vari-
ables. Patients with a larger number of tumor-involved
lymph nodes presented higher levels of serum proMMP-2
(Figure 3).
The correlation of proMMP-2 and steroid receptor lev-
els was shown to be weak negative and statistically insig-
nificant (p=0.149). Patients with positive steroid recep-
tors showed a tendency towards lower levels of serum
proMMP-2 (Figure 4).
The serum proMMP-2 level in correlation with vascu-
lar invasion showed a weak, statistically insignificant
correlation (p=0.156).
PromMP-2 in relation to EIC also showed a weak,
negative and statistically insignificant correlation (p=
0.72). In patients with histologically confirmed EIC com-
ponent the level of serum proMMP-2 had a tendency to-
wards lower values.
A comparison of proMMP-2 and HER-2 protein did
not show any statistical significance (p=0.776). HER-
-2-positive patients had lower serum proMMP-2 levels
compared to HER-2-negative patients in whom the levels
of serum proMMP-2 were higher.
Discussion
Breast tumor is a pathohistologically and clinically
heterogeneous disease, and of different prognostic pat-
terns. The most common is a malignant female tumor
that accounts for 27% of all malignant diseases in women.
It has been generally accepted that the different clini-
cal course and different outcomes of the disease in pa-
tients with the same histologic tumor type are the result
of molecular differences between carcinomas.
Recently, the importance of proteases related to the
tumor, tumor invasion and metastasis has been shown in
various tumors, including the tumor of the breast. Ma-
trix metalloproteinases are being intensely investigated
as a potential prognostic factor in breast cancer pa-
tients7,8.
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Fig. 1. Correlation proMMP-2 and age of the healthy control.
Fig. 2. Correlation proMMP-2 and age of all study patients. Fig. 4. Correlation proMMP-2 level and steroid receptor levels.
Fig. 3. Correlation proMMP-2 level with the number of positive
lymph nodes.
MMP-2 is one of MMP family members involved in
the process of tumor invasion and metastasis, first of all
for its unique ability to disintegrate the type IV collagen,
which is the main component of cell basement mem-
brane, and this is considered to play a crucial role in inva-
sion of malignant tumors. Recent studies show MMP-2 to
be intensely and invariably related to breast cancer, and
this can be found in serum, urine, plasma and tissue of
breast cancer patients. In biological systems and fluids,
MMPs occur as inactive proenzymes, active enzymes and
inactive enzymes bound by various inhibitors5,10,12.
Some authors show the high level of serum MMP-2 to
be related to a poorer prognosis in patients with positive
axillary lymph nodes. Moses et al. report that that urine
MMP-2 concentrations are increased in patients with
breast cancer. For diagnostic purposes, Duffy recom-
mends the assessment of MMP-2 as a prognostic factor in
breast cancer13,14.
Several recent studies have shown that the increased
expression of tissue MMP-2 in breast carcinoma is re-
lated to poorer prognosis15,16. While the results of a series
of studies of matrix metalloproteinase-2 expression in tu-
mor tissue are largely in accord that the increased ex-
pression is an adverse predictor and prognosticator in
breast cancer patients, this cannot be confirmed for the
circulating MMP-2.
Which form of the circulating MMP-2 yields the best
information about tumor progression and survival re-
mains to be elucidated.
La Rocca et al. report on the results of their study
showing a negative correlation between MMP-2 and es-
trogen receptors17. Sheen-Chen et al. publish their study
demonstrating a statistically significant difference be-
tween MMP-2 concentrations assessed for two groups of
breast cancer patients and report on the higher concen-
tration of MMP-2 in patients with lymph node positive
cancer and higher stage of the disease18.
In their publication, Kuvaja et al. report for the first
time on the inverse correlation of the concentration of to-
tal proMMP-2 and traditional prognostic factors (positive
lymph nodes, high histologic tumor grade, higher stage
of the disease) in breast cancer patients. There is a refer-
ence that the level of the circulating MMP-2 does not cor-
relate with the tissue levels. It is assumed that the total
proMMP-2 and proMMP-2-TIMP-2 complex levels in pa-
tients’ sera prior to surgery suggest the presence of the
disease, whereas the active form of MMP-2 could be re-
lated to the progression and spread of cancer and might
suggest overall patient survival4.
At the tissue level, the increased concentration of ac-
tive MMP-2 may be explained by proteolysis and cell mi-
gration during the metastatic spread of the disease. This
could also explain the concurrent lower value of serum
active MMP-2 for its efficacy at the tissue level during
the spread of carcinoma.
This study is aimed at assessing the significance of
the obtained levels of proMMP-2 and proMMP-2-TIMP-2
complex as the pro-enzyme form of MMP-2 in preopera-
tive serum of breast cancer patients. It has been assumed
that the proMMP-2 concentration should differ in pa-
tients with different histologic grade of the disease. An
attempt has been made to assess the significance of
proMMP-2 in relation to tumor size, hormone receptor
status, axillary lymph nodes, patient age, EIC, vascular
invasion and HER-2 protein. Patients were classified
into three groups according to the histologic grade of
their tumor to be compared with the control group of 50
healthy women.
A comparison of the serum proMMP-2 level between
the healthy controls and patients classified into his-
tologic grade groups does not show any statistical signifi-
cance of the difference between proMMP-2 concentra-
tions, although the grade III group had the highest
values of proMMP-2.
The study of Kuvaja et al. showed that the patients
had higher serum levels of proMMP-2 in relation to
healthy controls, and also lower serum levels of proMMP-
-2-TIMP-2 complex than the healthy controls4.
The correlation between the healthy control pro-
MMP-2 level and age showed a tendency towards lower
values in old age, although without any statistical signifi-
cance (p=0.175). In older age, levels of the majority of
enzymes are physiologically reduced, and this correlation
can thus be explained as a physiological event. On the
other hand, comparing proMMP-2 levels with patient age
a positive, statistically significant correlation was found,
i.e. proMMP-2 had a tendency of increase towards higher
levels in the grade I patients of old age (p=0.0147) as
compared to all study patients (p=0.0021).
A comparison of proMMP-2 by tumor diameter, i.e. tu-
mor size revealed a weak positive and statistically insig-
nificant correlation (p=0.157). In their study Shu-Chih
Liu et al. report also about the positive linear correlation
between tissue and serum proMMP-2 levels and tumor
size19. ProMMP-2 in relation to the number of positive
lymph nodes in the axilla showed a weak positive and sta-
tistically insignificant correlation. Sirpa Leppa et al. did
not find any statistically significant correlation between
the serum MMP-2 levels and lymph node status, age and
hormone receptors, and in larger tumors, the MMP-2
level showed a tendency towards an increase20.
A comparison of proMMP-2 and HER-2 protein did
not show any statistical significance. Patients who were
HER-2-positive had lower proMMP-2 levels, and HER-
-2-negative patients showed higher levels of serum pro-
MMP-2. These correlation results for HER-2 protein
comply with the results obtained by the Finnish authors4.
This study was aimed at comparing the proMMP-2 en-
zyme levels obtained in three patient groups with their
HER-2 protein status as a prognostic factor and patients’
age. The assessed correlation values showed to be statis-
tically significant in relation to age of grade I patients
and overall age in all patient groups. The total MMP-2
level was also assessed in this study. The study to distin-
guish the proMMP-2 from proMMP-2-TIMP-2 complex
levels by Kuvaja et al. show the proMMP-2 levels to be
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higher in patients in relation to healthy controls, in con-
trast to the proMMP-2-TIMP-2 complex levels which
show to be higher in healthy controls21.
In this study, a comparison of proMMP-2 levels in
three patient groups did not show any statistically signif-
icant difference. The highest proMMP-2 levels, including
the highest overall mean, were reported for the grade III
group.
The obtained results apply to the total proMMP-2
without its dividing into proMMP-2 and proMMP-2-
-TIMP-2 complexes. The prognostic value of the circulat-
ing MMP-2 remains to be documented on a larger patient
sample and a longer follow-up. Simplicity in obtaining
samples as well as sample availability are also of utmost
importance for both the assessment and longer follow-up
of the circulating MMP-2.
Conclusion
The serum proMMP-2 levels did not show any statisti-
cally significant difference between the study patients
classified into three groups according to their tumor dif-
ferentiation grade (grades I, II and III). The proMMP-2
levels obtained from patients’ sera in relation to their
pathohistological prognostic factors revealed a statisti-
cally significant correlation between proMMP-2 and age
in patients with histologic grade I tumors, including
overall age in patient groups.
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RAZINA SERUMSKE PRO-MATRIKS METALOPROTEINAZE -2 KAO PROGNOSTI^KOG
POKAZATELJA U BOLESNICA S DUKTALNIM INVAZIVNIM KARCINOMOM DOJKE
S A @ E T A K
U ovoj studiji analizirano je 150 bolesnica s duktalnim invazivnim karcinomom dojke koje su operirane u Klinici za
tumore od sije~nja 2006. do sije~nja 2007. godine. Kontrolnu skupinu ~inilo je 50 zdravih `ena. Bolesnice su svrstane u
tri skupine, ovisno o stupnju diferenciranosti tumora, gradus I, II, III. Svaka supina sadr`avala je po 50 bolesnica. Kod
bolesnica su analizirani dob, veli~ina i stupanj diferenciranosti tumora, stanje pazu{nih limfnih ~vorova, postojanje
udaljenih metastaza, nalaz steroidnih receptora, vaskularna invazija u primarnom tumoru, prisutnost intraduktalne
komponente (EIK-a) u primarnom tumoru, izra`enost proteina HER-2. ProMMP-2 odre|ivana je i u kontrolnoj skupi-
ni. Odre|ivana je ELISA metodom. Rezultati istra`ivanja pokazali su da nije bilo razlike u koncentraciji proMMP-2
izme|u tri skupine bolesnica i kontrolne skupine. Nije na|ena statisti~ki zna~ajna razlika u serumskoj koncentraciji
proMMP-2 izme|u tri skupine bolesnica premda je skupina gradusa III imala najvi{e vrijednosti i te`nju ka statisti~koj
zna~ajnosti. Usporedbom proMMP-2 s prognosti~kim ~imbenicima u skupini histolo{kog gradusa I na|ena je statisti~ki
zna~ajna korelacija proMMP-2 i dobi bolesnica. Nije na|ena statisti~ki zna~ajna povezanost cirkuliraju}e proMMP-2 s
ostalim patohistolo{kim prognosti~kim ~imbenicima.
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